Nov 6, 2023 · A new approach that combines CAR T cells with serial mRNA vaccine injections facilitates robust anti-neoplastic activity in patients with genitourinary cancers, which will pave the way for...

Non-viral vector chimeric antigen receptor (CAR)-T cells have garnered increasing attention due to their ability to efficiently eradicate cancer cells while mitigating undesirable side effects.

Dec 1, 2024 · Intriguingly, cell-targeting delivery of messenger RNA (mRNA) with ionizable lipid nanoparticles (mRNA-LNPs) is able to efficiently and precisely engineer T cells and other immune cells in vivo to perform their functions.

Feb 1, 2024 · Chimeric antigen receptor (CAR) T therapy is a game changer in cancer immunotherapy and beyond. CAR natural killer (NK) cells and CAR macrophages show tremendous potential as Trojan horses for solid tumors. mRNA is emerging as a new class of therapeutic modalities, holding great promise for mRNA vaccines and …

Messenger RNA (mRNA) has been explored as a promising strategy for inducing transient CAR expression in T cells to mitigate the adverse effects associated with viral vectors, but it most commonly requires electroporation for T cell mRNA delivery, which can be cytotoxic.

Oct 21, 2024 · The rationale is that mRNA vaccines can induce a strong initial immune response, while checkpoint inhibitors or CAR T-cells can enhance and sustain the attack on the tumor.

Aug 5, 2024 · Messenger RNA (mRNA)-based transient expression of CAR shows optimal safety profiles and provides promising opportunities to address existing challenges of viral vector-based CAR-T therapies and to meet emerging medical needs in noncancerous indications.

Mar 28, 2025 · Chimeric antigen receptor T cell (CAR-T) therapy has revolutionized cancer immunotherapy but continues to face significant challenges that limit its broader application, such as antigen targeting, the tumor microenvironment, and cell persistence, especially in solid tumors. Meanwhile, the global implementation of mRNA vaccines during the COVID-19 pandemic has highlighted the transformative ...

Feb 28, 2025 · Successful therapeutic outcome of CAR-T relies on stable expression of CAR transgene in T cells, this objective is accomplished through the delivery of CAR transgene utilizing integrating gamma retroviral (RV) or lentiviral (LV) vectors (Table 1).

Jan 23, 2025 · In this study, the optimization of CAR-mRNA for T cell applications is investigated, focusing on the impact of mRNA modifications, in vitro transcription protocols, and purification techniques on the translation efficiency and immunogenicity of mRNA.